Nifekalant for Patients With OHCA rone recipients. 2 Moreover, NIF decreases the defibrillation threshold, 10 whereas amiodarone does not. 11 On the basis of these unique features of NIF, the present study was designed to investigate the feasibility of NIF as a life-saving therapy to defibrillation for victims of out-ofhospital cardiac arrest.
Methods

Study Design
The J-PULSE (Japanese Population-based Utstein-style study with basic and advanced Life Support Education) study was a multi-center registry study with 4 participating institutes located at the northern urban area of Osaka, Japan; National Cerebral and Cardiovascular Center, Senri Critical Care Medical Center, Mishima Emergency and Critical Care Center, and Osaka University Hospital Trauma and Acute Critical Care Center.
Eligible patients were those treated with NIF because they were adults with electrocardiographically documented out-ofhospital VF, not due to trauma, drowning and acute airway obstruction, or other cardiac rhythms that converted to VF, and because the VF was resistant to 3 counter-shocks, at least 1 dose of intravenous epinephrine, and fourth defibrillator shock. Therapy using NIF did not include the general advice of the Cardiopulmonary Resuscitation and Emergency Cardiovascular Care to administer amiodarone, 12 but instead was used as a replacement for this guideline. NIF was intravenously administered at the dose of 0.15-0.30 mg/kg body weight and then further direct counter-shock was delivered. If VF persisted after further shocks, NIF was additionally used at the dose of 0.15-0.30 mg/kg body weight, and attempts at resuscitation. Percutaneous extracorporeal membrane oxygenation (ECMO) 13 was applied for hemodynamic failure when patients were in refractory cardiac arrest, defined as an absence of return to spontaneous circulation after continuous cardiopulmonary resuscitation (CPR) or in refractory shock, defined as shock not responding to optimal conventional treatment.
This study was approved by the Institutional Review Board, including its provisions for waiver of informed consent. If the patients died, the informed consent was obtained from the family.
Data Recording
Pre-hospital data of the patients' course were prospectively obtained from the ambulance call report in the Utstein-style, 14 including sex, age, initial cardiac rhythm, time course of resuscitation, type of bystander-initiated CPR, return of spontaneous circulation (ROSC) and hospital admission. The times of emergency medical services (EMSs) call receipt and arrival of ambulance car at the scene of cardiac arrest were recorded automatically at EMS center. Data were also obtained from hospital charts, including the prevalence of adverse events of TdP.
Data Analysis
The endpoint in the present study was survival to admission to the hospital. Thus, patients who died in the emergency room were not considered to have been admitted. The endpoint also included ROSC after administration of NIF, which was defined as the documented presence of a measurable pulse and blood pressure. The relationship of clinical and therapeutic variables to survival and ROSC were determined with Fisher's exact test. A value of P<0.05 was considered to be statistically significant.
Results
Between February 2006 and February 2007, 23 patients (M 21/F 2, age 66±12 years) were interim registered. From 4 participating institutes (overall annual number of out-ofhospital cardiac arrest, 478; victims of cardiac origin, 173), 15, 5, 2 and 1 patients were enrolled, respectively. Among them, 2 patients did not give informed consent and 4 patients did not meet the entry criteria. Finally, 17 patients (M/F 15/2; median age (range) 68 (46-89) years) were studied in the present study (Figure 1 ). Initial electrocardiogram (ECG) rhythm was VF in 13 patients (76%) and asystole in the remaining 4 patients. A total of 12 patients (71%) were witnessed by a bystander, and 7 patients (41%) received bystander CPR by a witness. A doctor car was used in 11 patients (65%), and ECMO was used in 13 patients (76%). Table 1 . *Survival to admission to the hospital. YASUDA S et al.
The characteristics and the time interval from the EMS call in individual patients were summarized in Table 1 . The median time from a call for EMS to the first shock was 12 (6-26) min. In particular, in patients who were witnessed by a bystander, the median time from the collapse to the EMS call was 1 min. The median time from the first shock to the NIF administration was 25.5 (9-264) min and the median usage dose of NIF was 25 (15-210) mg.
When excluding 3 patients in whom ECMO was applied before NIF administration (Figure 1) , the rate of ROSC was 86% (n=12 out of 14 patients) and the rate of admission alive to the hospital was 79% (n=11 out of 14 patients). The time from NIF administration to ROSC was within 10 min in 3 patients, 10 to 30 min in 6 patients and over 30 min in 3 patients, respectively (median: 20 min). One ROSC patient died in the emergency room and were not admitted to the hospital. One patient developed TdP (7%), which was transiently induced and disappeared after discontinuing the administration of NIF (Figure 2) .
We then determined the relationship of clinical and therapeutic variables to ROSC and admission alive ( Table 2 ). The rate of admission alive to the hospital was 91.7% in patients in whom initial ECG rhythm was VF, whereas it was 0% in those in whom initial ECG rhythm was asystole (P=0.033). The ROSC rate was 91.7% in patients in whom initial ECG rhythm was VF, whereas it was 50% in those in whom initial ECG rhythm was asystole (P=0.275). Between patients with and without ECMO, the rate of admission alive to the hospital (with ECMO, 90% vs without ECMO, 50%) and the ROSC rate (with ECMO, 90% vs without ECMO, 75%) did not differ in the present study.
Discussion
The major finding of the present multicenter registry study is that the ROSC rate and the rate of admission alive to the hospital in out-of-hospital VF patients treated with NIF was high, 86% and 79%, respectively.
NIF for Out-of-Hospital Cardiac Arrest
According to the Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, 12 intravenous amiodarone should be considered for VF or pulseless VT patients after 3 unsuccessful direct counter-shocks. However, amiodarone was not commercially available until June, 2007 in Japan. Therefore, as alternative for amiodarone, the present study was designed to investigate the feasibility of NIF as a life-saving therapy to defibrillation for victims of out-ofhospital cardiac arrest.
NIF has several advantageous characteristics particularly for emergency care. First, NIF is easily soluble and applicable to secure golden time for resuscitation. Second, its half life is relatively short (T1/2β, 1.53±0.23 h), 5 achieving rapid action and clearance. Third, NIF has only a small cardiac depressant effect and might improve the defibrillation threshold. Fourth, an extracardiac adverse event is not usual.
We previously reported that the intravenous administration of NIF was useful in the emergency treatment of inhibiting drug-refractory VT/VF in high-risk patients, including those with extensive anterior acute myocardial infarction and those who had been already treated with oral amiodarone, oral sotalol, and/or implantable cardioverter defbrillator. 6 However, there have been few single center studies regarding the effect of NIF on patients with shock-resistant, out-ofhospital VF. The rate of admission alive to the hospital was 67% (37 survivors of 55 patients treated with NIF), 15 which was comparable with the present results, where the data were collected from 4 established emergency departments. However, over 20 min spent until NIF was administered following the first shock. When considering the characteristics unique of NIF that decreases the defibrillation threshold, 10 the earlier NIF can be used in the course of cardiac arrest, the greater is the likelihood of at least acute survival.
While proarrhythmic properties of amiodarone are relatively minor as demonstrated in the previous studies, 16 proarrhythmic TdP is the major adverse effect of NIF. 6,17 However, as reported in the previous single center study, the occurrence of TdP was 5% (1 of 21 patients treated with NIF), 18 as low as the present result. The previous study demonstrated that the sensitivity of IKr channels could be modified by its genetic polymorphism or surroundings such as catecholamine, potassium, and pH. 19 In the present study, the median usage dose of NIF was 25 mg. If a patient's body weight is 60-70 kg, the standard ini- tial dose should be ~20 mg, 0.3 mg/kg body weight. Figure 3 shows the simulation of the pharmacokinetics of NIF when the bolus administration at 0.3 mg/kg body weight was performed in a minute in healthy subjects (unpublished data). In this compartment model, the blood concentration of NIF appears to be comparable with that following the standard administration at 0.3 mg/kg body weight/5 min. Although the blood concentration could peak within 10 min in this simulation, it often took 10 to 30 min to recover spontaneous circulation in the present collapsed patients with limited cardiac output by closed chest massage. 20 
Study Limitations
Several limitations of the present study should be mentioned. First, the small number of patients precludes any firm conclusion in this setting designed as a pilot study. Further larger clinical studies with a blinded, randomized design are required. However, resuscitation for out-of-hospital cardiac arrest patients is always critical and is a race against time. It is therefore difficult to explain the study design and its process (eg, blindness and randomization) to potential trial participants. Second, the prognosis after the admission, especially the survival to hospital discharge, was not presented. Third, since intended as a pilot study of various critically ill patients, the present data did not include type of disease, cardiac function (after ROSC or coronary intervention, or under percutaneous ECMO support), serum K + and pH concentrations. Fourth, in the recent intensive strategy of the emergency medicine, 21-24 it seems to be hard to distinguish the pharmacological effect of NIF from the mechanical effect of percutaneous ECMO (with the adjunctive therapeutic hypothermia) on CPR.
Conclusions
The present findings indicate that intravenous administration of NIF seems to be feasible as a potential life-saving therapy for advanced cardiac life-support in patients with out-ofhospital VF and therefore further study is warranted.
